ISRG:NASDAQIntuitive Surgical, Inc. Analysis
Data as of 2026-05-27 - not real-time
$417.95
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Intuitive Surgical (ISRG) is trading at $417.95, well under its 20‑day ($441.23), 50‑day ($456.18) and 200‑day ($495.55) moving averages, signaling a bearish short‑term price trend. The RSI of 36 and a bearish MACD histogram (-0.35) further underscore recent momentum weakness, while the 30‑day volatility of 40% and a beta near 0.93 suggest the stock is more volatile than the market. On the valuation side, the trailing P/E of 50.9 dwarfs the industry average of 27.4 and the DCF‑derived fair value of $223.19, indicating the market is pricing in substantial future growth despite current overvaluation.
Fundamentally, ISRG delivers strong financial performance with 23% revenue growth, 66% gross margin and 31% operating margin, supported by $4.5 B of cash and zero debt. Analysts remain optimistic, assigning a “Buy” consensus and a median price target of $578.5, implying roughly 37% upside from today’s price. Recent headlines highlight continued innovation and a perceived bullish upside of ~35%, even as the stock slipped 7.2% post‑earnings, reflecting a mix of growth enthusiasm and short‑term price pressure.
Fundamentally, ISRG delivers strong financial performance with 23% revenue growth, 66% gross margin and 31% operating margin, supported by $4.5 B of cash and zero debt. Analysts remain optimistic, assigning a “Buy” consensus and a median price target of $578.5, implying roughly 37% upside from today’s price. Recent headlines highlight continued innovation and a perceived bullish upside of ~35%, even as the stock slipped 7.2% post‑earnings, reflecting a mix of growth enthusiasm and short‑term price pressure.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Technical weakness: price below key moving averages and bearish MACD
- Near support at $414.30 limiting downside
- Recent earnings miss causing 7.2% price decline
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Robust 23% revenue growth and high operating margins
- Strong cash position with no debt
- Analyst consensus and median target price suggesting ~37% upside
Long Term
> 3 yearsPositive
Model confidence: 9/10
Key Factors
- Sustainable competitive moat from the da Vinci platform
- Expansion into diagnostic endoluminal procedures (Ion system)
- Long‑term secular demand for minimally invasive surgery
Key Metrics & Analysis
Financial Health
Revenue Growth23.00%
Profit Margin28.15%
P/E Ratio50.9
ROE17.23%
ROA10.24%
P/B Ratio8.5
Op. Cash Flow$3.4B
Free Cash Flow$2.3B
Industry P/E27.4
Technical Analysis
TrendBearish
RSI36.1
Support$414.30
Resistance$463.50
MA 20$441.23
MA 50$456.18
MA 200$495.55
MACDBearish
VolumeStable
Fear & Greed Index91.89
Valuation
Fair Value$223.19
Target Price$572.68
Upside/Downside37.02%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.93
Volatility40.42%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.